DIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certification
BROSSARD, Quebec, April 16, 2024 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or “the Company”) (TSX Venture: ADK) (OTCQB:DGNOF), a provider of healthcare services in early detection of certain critical health issues, announces today that it is working on getting new Health Canada and FDA approval on 4 additional AI analysis modules for commercialisation during Q3 2024.
Related news for (DGNOF)
- DIAGNOS Welcomes Former White House Economic Adviser Dr. Tomas J. Philipson to its Advisory Board for the US Market
- DIAGNOS Announces the Engagement of Allele Capital Partners
- DIAGNOS Announces Amendment to Convertible Debentures
- DIAGNOS announces major advances in Cybersecurity certification by the Cyber Defense Operations Center (COCD) for its CARA System application
- DIAGNOS Provides Additional Information on Amendment to Convertible Debentures